In a study of NSCLC patients treated with immunotherapy, patients with TP53/KRAS co-mutation were found to have a significantly longer PFS (5.8 vs. 2.6 months, p = 0.005) [52]. Here, TP53 is linked to non-small cell lung carcinoma.